Literature DB >> 16900551

A sequential procedure for monitoring clinical trials against historical controls.

Xiaoping Xiong1, Ming Tan, James Boyett.   

Abstract

In this paper, we develop a sequential procedure to monitor clinical trials against historical controls. When there is a strong ethical concern about randomizing patients to existing treatment because biological and medical evidence suggests that the new treatment is potentially superior to the existing one, or when the enrollment is too limited for randomization of subjects into experimental and control groups, one can monitor the trial sequentially against historical controls if the historical data with required quality and sample size are available to form a valid reference for the trial. This design of trial is sometimes the only alternative to a randomized phase III trial design that is intended but not feasible in situations such as above. Monitoring this type of clinical trial leads to a statistical problem of comparing two population means in a situation in which data from one population are sequentially collected and compared with all data from the other population at each interim look. The proposed sequential procedures is based on the sequential conditional probability ratio test (SCPRT) by which the conclusion of the sequential test would be virtually the same as that arrived at by a non-sequential test based on all data at the planned end of the trial. We develop the sequential procedure by proposing a Brownian motion that emulates the test statistic, and then proposing an SCPRT that is adapted to the special properties of the trial. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16900551     DOI: 10.1002/sim.2635

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  Survival trial design and monitoring using historical controls.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Pharm Stat       Date:  2016-06-15       Impact factor: 1.894

2.  Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.

Authors:  Maryam Fouladi; Murali Chintagumpala; David Ashley; Stewart Kellie; Sridharan Gururangan; Tim Hassall; Lindsey Gronewold; Clinton F Stewart; Dana Wallace; Alberto Broniscer; Gregory A Hale; Kimberly A Kasow; Thomas E Merchant; Brannon Morris; Matthew Krasin; Larry E Kun; James M Boyett; Amar Gajjar
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

3.  Creation and implementation of a historical controls database from randomized clinical trials.

Authors:  Jigar R Desai; Edward A Bowen; Mark M Danielson; Rajasekhar R Allam; Michael N Cantor
Journal:  J Am Med Inform Assoc       Date:  2013-02-28       Impact factor: 4.497

4.  Group sequential design for historical control trials using error spending functions.

Authors:  Jianrong Wu; Yimei Li
Journal:  J Biopharm Stat       Date:  2019-11-12       Impact factor: 1.051

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.